サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1655388

クラッベ病治療の世界市場

Krabbe Disease Treatment

出版日
ページ情報
英文 194 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.82円
クラッベ病治療の世界市場
出版日: 2025年02月14日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 194 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

クラッベ病治療の世界市場は2030年までに22億米ドルに達する

2024年に15億米ドルと推定されるクラッベ病治療の世界市場は、分析期間2024-2030年にCAGR 6.2%で成長し、2030年には22億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである抗けいれん薬は、CAGR 5.3％を記録し、分析期間終了時には8億2,350万米ドルに達すると予測されます。筋弛緩剤セグメントの成長率は、分析期間中CAGR 5.9%と推定されます。

米国市場は4億1,670万米ドルと推定、中国はCAGR 5.9％で成長予測

米国のクラッベ病治療市場は、2024年には4億1,670万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに3億4,060万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは5.9%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ5.7%と5.1%と予測されています。欧州では、ドイツがCAGR 5.0%で成長すると予測されています。

クラッベ病治療の世界市場- 洞察と医療の進歩

クラッベ病とは何か、なぜ希少疾患研究で重要な焦点なのか？

クラッベ病は、グロボイド細胞白質ジストロフィーとしても知られ、中枢神経系を侵すまれでしばしば致死的な遺伝性疾患です。GALC遺伝子の変異によって引き起こされ、脳内にガラクト脂質が蓄積し、神経細胞を絶縁しているミエリン鞘が破壊されます。この進行性の脱髄により、発達遅延、筋力低下、視力低下などの重篤な神経障害が引き起こされ、しばしば幼児期に死に至る。クラッベ病は、その希少性と症状の重篤性から、希少疾患研究の重要な焦点となっています。クラッベ病の診断と治療にはかなりの課題があり、現在の治療法は主に対症療法とごく初期の骨髄移植に限られています。しかし、現在進行中の調査では、より効果的で治癒の可能性のある選択肢を提供するために、遺伝子治療や酵素補充療法を含む新しい治療アプローチが模索されています。

遺伝子治療と早期診断の進歩はクラッベ病治療にどのような影響を与えているか？

遺伝子治療と早期診断の進歩は、クラッベ病治療の状況に大きな影響を与え、罹患者とその家族に新たな希望を提供しています。欠陥のあるGALC遺伝子の機能的コピーを患者の細胞に導入する遺伝子治療は、最も有望な研究分野の一つです。前臨床試験および初期段階の臨床試験から、遺伝子治療には、脳内の毒性蓄積を防ぐのに必要な酵素活性を回復させることによって、クラッベ病の進行を止めたり、あるいは逆転させたりする可能性があることが示されています。さらに、新生児スクリーニングプログラムの改善により、クラッベ病の早期診断が可能になりつつあります。早期発見により、造血幹細胞移植（HSCT）のような介入が可能になります。これらの進歩は、より効果的な治療戦略への道を開き、クラッベ病患者の予後を改善しています。

クラッベ病治療市場が直面する課題とは？

クラッベ病治療市場は、疾患の希少性、治療の複雑性、研究開発や市場開拓に伴う高コストなど、いくつかの課題に直面しています。希少疾患であるクラッベ病は患者数が少ないため、製薬企業が研究開発に投資する経済的インセンティブが制限される可能性があります。さらに、クラッベ病の治療、特に進行期の治療は非常に複雑で、神経科医、遺伝学者、緩和ケアの専門家など、集学的治療が必要となることが多いです。遺伝子治療や幹細胞移植などの治療には法外な費用がかかるため、治療へのアクセスや保険償還への懸念が生じる。さらに、効果的な治療法の開発には、この病気の根本的なメカニズムを深く理解する必要があり、血液脳関門を越えて治療薬を届けることが難しいという課題もあります。このような課題に対処するため、研究者、ヘルスケアプロバイダー、患者擁護団体、製薬企業が協力してイノベーションを推進し、新たな治療法を必要としている人々に確実に届けることに注目が集まっています。

クラッベ病治療市場の成長を促進する要因は？

クラッベ病治療市場の成長は、遺伝子研究の進歩、認知度の向上と早期診断、新規治療法の開発など、いくつかの要因によって牽引されています。遺伝子研究の急速な進展は、クラッベ病の根底にある分子メカニズムの理解を深め、遺伝子治療や酵素補充療法などの標的治療開発への道を開いています。また、新生児スクリーニングプログラムや早期診断ツールの拡充も、治療成績の向上に不可欠な早期介入を可能にし、成長を後押ししています。さらに、製薬業界における希少疾患への注目の高まりは、政府の優遇措置や希少疾病用医薬品の指定によって支えられており、クラッベ病の新たな治療法開発への投資に拍車をかけています。このような進歩が続くにつれ、クラッベ病治療の市場は成長し、患者やその家族に新たな希望をもたらすことが期待されます。

セグメント

治療薬（抗けいれん薬、筋弛緩薬、造血幹細胞移植（HSCT）、その他の治療薬）

調査対象企業の例（注目の42社）

  • Abbott Laboratories
  • CENETOGENE N.V.
  • GlaxoSmithKline
  • Johnson & Johnson
  • Novartis AG
  • Pfizer
  • Sanofi-Aventis SA
  • Shire
  • Teva Pharmaceutical Industries Ltd.
  • UCB Pharmaceuticals

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP12910

Global Krabbe Disease Treatment Market to Reach US$2.2 Billion by 2030

The global market for Krabbe Disease Treatment estimated at US$1.5 Billion in the year 2024, is expected to reach US$2.2 Billion by 2030, growing at a CAGR of 6.2% over the analysis period 2024-2030. Anticonvulsants, one of the segments analyzed in the report, is expected to record a 5.3% CAGR and reach US$823.5 Million by the end of the analysis period. Growth in the Muscle Relaxants segment is estimated at 5.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$416.7 Million While China is Forecast to Grow at 5.9% CAGR

The Krabbe Disease Treatment market in the U.S. is estimated at US$416.7 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$340.6 Million by the year 2030 trailing a CAGR of 5.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 5.7% and 5.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.0% CAGR.

Global Krabbe Disease Treatment Market - Insights & Medical Advancements

What Is Krabbe Disease and Why Is It a Significant Focus in Rare Disease Research?

Krabbe disease, also known as globoid cell leukodystrophy, is a rare and often fatal genetic disorder that affects the central nervous system. It is caused by mutations in the GALC gene, which lead to the accumulation of galactolipids in the brain, resulting in the destruction of the myelin sheath that insulates nerve cells. This progressive demyelination causes severe neurological impairment, including developmental delays, muscle weakness, and vision loss, often leading to death in early childhood. Due to its rarity and the severe nature of its symptoms, Krabbe disease is a significant focus in rare disease research. The condition poses considerable challenges for diagnosis and treatment, with current therapeutic options being limited primarily to symptomatic management and bone marrow transplantation in very early stages. However, ongoing research is exploring novel treatment approaches, including gene therapy and enzyme replacement therapy, to provide more effective and potentially curative options.

How Are Advancements in Gene Therapy and Early Diagnosis Impacting Krabbe Disease Treatment?

Advancements in gene therapy and early diagnosis are significantly impacting the landscape of Krabbe disease treatment, offering new hope for affected individuals and their families. Gene therapy, which involves delivering a functional copy of the defective GALC gene to the patient’s cells, is one of the most promising areas of research. Preclinical studies and early-phase clinical trials have shown that gene therapy has the potential to halt or even reverse the progression of Krabbe disease by restoring the enzyme activity needed to prevent toxic buildup in the brain. Additionally, improvements in newborn screening programs are enabling earlier diagnosis of Krabbe disease, which is crucial for the timely initiation of treatment. Early detection allows for interventions such as hematopoietic stem cell transplantation (HSCT), which has been shown to be more effective when performed before the onset of symptoms. These advancements are paving the way for more effective treatment strategies and improving the prognosis for patients with Krabbe disease.

What Challenges Does the Krabbe Disease Treatment Market Face?

The Krabbe disease treatment market faces several challenges, including the rarity of the condition, the complexity of treatment, and the high costs associated with research and therapy development. As a rare disease, Krabbe disease affects a small patient population, which can limit the financial incentives for pharmaceutical companies to invest in research and development. Additionally, the treatment of Krabbe disease, particularly in its advanced stages, is highly complex and often requires multidisciplinary care, including neurologists, geneticists, and palliative care specialists. The cost of treatments, such as gene therapy and stem cell transplantation, can be prohibitively high, raising concerns about accessibility and reimbursement. Furthermore, the development of effective therapies is challenged by the need for a deep understanding of the disease’s underlying mechanisms and the difficulties in delivering treatments across the blood-brain barrier. To address these challenges, there is a growing focus on collaboration between researchers, healthcare providers, patient advocacy groups, and pharmaceutical companies to drive innovation and ensure that emerging therapies reach those in need.

What Factors Are Driving Growth in the Krabbe Disease Treatment Market?

The growth in the Krabbe disease treatment market is driven by several factors, including advancements in genetic research, increased awareness and early diagnosis, and the development of novel therapies. The rapid progress in genetic research is leading to a better understanding of the molecular mechanisms underlying Krabbe disease, paving the way for the development of targeted therapies such as gene therapy and enzyme replacement therapy. The expansion of newborn screening programs and early diagnostic tools is also driving growth by enabling earlier intervention, which is critical for improving treatment outcomes. Additionally, the increasing focus on rare diseases within the pharmaceutical industry, supported by government incentives and orphan drug designations, is spurring investment in the development of new treatments for Krabbe disease. As these advancements continue, the market for Krabbe disease treatment is expected to grow, offering new hope for patients and their families.

SCOPE OF STUDY:

The report analyzes the Krabbe Disease Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Therapy (Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT), Other Therapies)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 42 Featured) -

  • Abbott Laboratories
  • CENETOGENE N.V.
  • GlaxoSmithKline
  • Johnson & Johnson
  • Novartis AG
  • Pfizer
  • Sanofi-Aventis SA
  • Shire
  • Teva Pharmaceutical Industries Ltd.
  • UCB Pharmaceuticals

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Krabbe Disease Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
    • Global Economic Update
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Awareness of Krabbe Disease Spurs Growth in the Treatment Market
    • Advancements in Gene Therapy Expand Addressable Market for Krabbe Disease Treatment
    • Rise in Newborn Screening Programs Propels Early Diagnosis and Treatment
    • Technological Innovations in Stem Cell Therapy Strengthen the Business Case for Krabbe Disease Treatments
    • Growing Focus on Rare Diseases and Orphan Drugs Throws the Spotlight on Krabbe Disease
    • Expansion of Specialized Treatment Centers Expands Access to Krabbe Disease Care
    • Increased Investment in R&D for Neurological Disorders Sustains Growth in Krabbe Disease Treatments
    • Growing Importance of Personalized Medicine Propels Innovation in Krabbe Disease Treatment
    • Shift Towards Multidisciplinary Care Models Strengthens the Treatment Ecosystem for Krabbe Disease
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Krabbe Disease Treatment Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Krabbe Disease Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Krabbe Disease Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Krabbe Disease Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Anticonvulsants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Anticonvulsants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Anticonvulsants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Muscle Relaxants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Muscle Relaxants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Muscle Relaxants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Hematopoietic Stem Cell Transplantation (HSCT) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Hematopoietic Stem Cell Transplantation (HSCT) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Hematopoietic Stem Cell Transplantation (HSCT) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Other Therapies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Krabbe Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 17: USA Recent Past, Current & Future Analysis for Krabbe Disease Treatment by Therapy - Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 18: USA Historic Review for Krabbe Disease Treatment by Therapy - Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: USA 15-Year Perspective for Krabbe Disease Treatment by Therapy - Percentage Breakdown of Value Sales for Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 20: Canada Recent Past, Current & Future Analysis for Krabbe Disease Treatment by Therapy - Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 21: Canada Historic Review for Krabbe Disease Treatment by Therapy - Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: Canada 15-Year Perspective for Krabbe Disease Treatment by Therapy - Percentage Breakdown of Value Sales for Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies for the Years 2015, 2025 & 2030
  • JAPAN
    • Krabbe Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 23: Japan Recent Past, Current & Future Analysis for Krabbe Disease Treatment by Therapy - Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 24: Japan Historic Review for Krabbe Disease Treatment by Therapy - Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: Japan 15-Year Perspective for Krabbe Disease Treatment by Therapy - Percentage Breakdown of Value Sales for Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies for the Years 2015, 2025 & 2030
  • CHINA
    • Krabbe Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 26: China Recent Past, Current & Future Analysis for Krabbe Disease Treatment by Therapy - Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: China Historic Review for Krabbe Disease Treatment by Therapy - Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: China 15-Year Perspective for Krabbe Disease Treatment by Therapy - Percentage Breakdown of Value Sales for Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies for the Years 2015, 2025 & 2030
  • EUROPE
    • Krabbe Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 29: Europe Recent Past, Current & Future Analysis for Krabbe Disease Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 30: Europe Historic Review for Krabbe Disease Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: Europe 15-Year Perspective for Krabbe Disease Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 32: Europe Recent Past, Current & Future Analysis for Krabbe Disease Treatment by Therapy - Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Europe Historic Review for Krabbe Disease Treatment by Therapy - Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: Europe 15-Year Perspective for Krabbe Disease Treatment by Therapy - Percentage Breakdown of Value Sales for Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies for the Years 2015, 2025 & 2030
  • FRANCE
    • Krabbe Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 35: France Recent Past, Current & Future Analysis for Krabbe Disease Treatment by Therapy - Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: France Historic Review for Krabbe Disease Treatment by Therapy - Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: France 15-Year Perspective for Krabbe Disease Treatment by Therapy - Percentage Breakdown of Value Sales for Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies for the Years 2015, 2025 & 2030
  • GERMANY
    • Krabbe Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 38: Germany Recent Past, Current & Future Analysis for Krabbe Disease Treatment by Therapy - Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Germany Historic Review for Krabbe Disease Treatment by Therapy - Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: Germany 15-Year Perspective for Krabbe Disease Treatment by Therapy - Percentage Breakdown of Value Sales for Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 41: Italy Recent Past, Current & Future Analysis for Krabbe Disease Treatment by Therapy - Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Italy Historic Review for Krabbe Disease Treatment by Therapy - Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: Italy 15-Year Perspective for Krabbe Disease Treatment by Therapy - Percentage Breakdown of Value Sales for Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Krabbe Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 44: UK Recent Past, Current & Future Analysis for Krabbe Disease Treatment by Therapy - Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: UK Historic Review for Krabbe Disease Treatment by Therapy - Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: UK 15-Year Perspective for Krabbe Disease Treatment by Therapy - Percentage Breakdown of Value Sales for Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 47: Rest of Europe Recent Past, Current & Future Analysis for Krabbe Disease Treatment by Therapy - Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Rest of Europe Historic Review for Krabbe Disease Treatment by Therapy - Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: Rest of Europe 15-Year Perspective for Krabbe Disease Treatment by Therapy - Percentage Breakdown of Value Sales for Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Krabbe Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 50: Asia-Pacific Recent Past, Current & Future Analysis for Krabbe Disease Treatment by Therapy - Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Asia-Pacific Historic Review for Krabbe Disease Treatment by Therapy - Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: Asia-Pacific 15-Year Perspective for Krabbe Disease Treatment by Therapy - Percentage Breakdown of Value Sales for Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies for the Years 2015, 2025 & 2030
  • REST OF WORLD
    • TABLE 53: Rest of World Recent Past, Current & Future Analysis for Krabbe Disease Treatment by Therapy - Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Rest of World Historic Review for Krabbe Disease Treatment by Therapy - Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: Rest of World 15-Year Perspective for Krabbe Disease Treatment by Therapy - Percentage Breakdown of Value Sales for Anticonvulsants, Muscle Relaxants, Hematopoietic Stem Cell Transplantation (HSCT) and Other Therapies for the Years 2015, 2025 & 2030

IV. COMPETITION